HepaTx Corporation (YC S18)
A New Alternative To Liver Transplants
https://wefunder.com/hepatx
Total raised on Wefunder: 123161
Total investors: 69
Quick facts
- Breakthrough therapeutic Hx-001 is designed to regenerate liver and reduces the need for transplants
- Addressing $20B+ liver disease crisis affecting 1/5 adults, 70% cheaper than transplants
- Preclinical studies show encouraging signs of reduced liver damage, inflammation, and fibrosis
- Prestigious Mayo Clinic license agreement brings expertise to reduce manufacturing and clinical risk
- Raising $1.2M to unlock manufacturing readiness and studies to enter human trials within 24 months
- Proprietary ProteoTrack diagnostic system offers a future second revenue stream
- Backed by YC and Stanford StartX, raised > $4.2M with ~$700K in grants
- Deeply experienced biotech leadership and scientific advisors